211 related articles for article (PubMed ID: 31152369)
1. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
[TBL] [Abstract][Full Text] [Related]
2. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
3. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Gündüz T; Kürtüncü M; Eraksoy M
Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
[No Abstract] [Full Text] [Related]
4. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
Członkowska A; Smoliński Ł; Litwin T
Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
[TBL] [Abstract][Full Text] [Related]
5. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
6. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
Sepúlveda M; Montejo C; Llufriu S; Sola-Valls N; Reyes D; Martinez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Baños N; Saiz A; Blanco Y
Mult Scler Relat Disord; 2020 Feb; 38():101483. PubMed ID: 31734621
[TBL] [Abstract][Full Text] [Related]
7. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with fingolimod rebound: A single center real-life experience.
Goncuoglu C; Tuncer A; Bayraktar-Ekincioglu A; Ayvacioglu Cagan C; Acar-Ozen P; Cakan M; Karabulut E; Karabudak R
Mult Scler Relat Disord; 2021 Nov; 56():103278. PubMed ID: 34655957
[TBL] [Abstract][Full Text] [Related]
9. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
[TBL] [Abstract][Full Text] [Related]
10. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
[TBL] [Abstract][Full Text] [Related]
11. Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Harirchian MH; Taalimi A; Siroos B
Mult Scler Relat Disord; 2015 Sep; 4(5):400-402. PubMed ID: 26346786
[TBL] [Abstract][Full Text] [Related]
12. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
[No Abstract] [Full Text] [Related]
13. Clinical activity after fingolimod cessation: disease reactivation or rebound?
Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
[TBL] [Abstract][Full Text] [Related]
14. Rebound activity after fingolimod cessation: A case - control study.
Barboza A; Gaitán MI; Alonso R; Ysrraelit MC; Luetic G; Liwacki S; Patrucco L; Halfon MJ; Burgos M; Mainella C; Pierdabuena R; Recchia L; Steinberg J; Tkachuk VA; Zanga G; Carra A; Chertcoff A; Fernandez Liguori N; Lazaro L; Menichini ML; Miguez J; Orzuza G; Palavecino A; Pappolla A; Pigretti S; Pita C; Ruiz E; Silva B; Zentil G
Mult Scler Relat Disord; 2022 Jan; 57():103329. PubMed ID: 35158443
[TBL] [Abstract][Full Text] [Related]
15. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
17. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
18. A case of early disease rebound after fingolimod discontinuation in a patient with multiple sclerosis and SARS-CoV-2 infection.
Giovannini B; Panelli D; Bianchi F; Siciliano G; Pasquali L
Neurol Sci; 2024 Jun; 45(6):2423-2426. PubMed ID: 38546935
[TBL] [Abstract][Full Text] [Related]
19. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
Gulec B; Everest E; Gorkey OD; Koc M; Tutuncu M; Saip S; Siva A; Uygunoglu U
Eur J Neurol; 2023 Sep; 30(9):2745-2751. PubMed ID: 37300847
[TBL] [Abstract][Full Text] [Related]
20. Different MRI patterns in MS worsening after stopping fingolimod.
Lapucci C; Baroncini D; Cellerino M; Boffa G; Callegari I; Pardini M; Novi G; Sormani MP; Mancardi GL; Ghezzi A; Zaffaroni M; Uccelli A; Inglese M; Roccatagliata L
Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e566. PubMed ID: 31086807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
